AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3475553
Drug: Double-blind placebo-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind placebo-controlled oral food challenges
Trial: 30392239
Drug: Anlotinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib (12 mg daily from day 1 to 14 of a 21-day cycle)
Trial: 20457982
Drug: No initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No initial treatment (control group)
Trial: 10527711
Drug: Liquid shark
RxNorm normalized name: shark preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid shark cartilage extract (7 ml)
Trial: 10527711
Drug: Liquid shark
RxNorm normalized name: shark preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid shark cartilage extract (21 ml)
Trial: 7138750
Drug: Cimetidine (oral)
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine (oral) for 2 months
Trial: 7138750
Drug: Cimetidine (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (intravenous infusion) for 48 hours
Trial: 26625755
Drug: High onion
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High onion group (HO; n=28) - 100-160 g/d of fresh yellow onion for 8 weeks
Trial: 26625755
Drug: Low onion
RxNorm normalized name: ONION
DrugBank: Onion (DB10548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low onion group (LO; n=28) - 30-40 g/d of small onion for 8 weeks
Trial: 21856592
Drug: Colesevelam HCl
RxNorm normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam HCl (3.75 g/d)
Trial: 12969093
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ropivacaine HCl rectally in 20 mL hydroxypropyl methylcellulose gel
Trial: 12969093
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ropivacaine HCl rectally in 40 mL hydroxypropyl methylcellulose gel
Trial: 12969093
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ropivacaine HCl rectally in 60 mL hydroxypropyl methylcellulose gel
Trial: 12969093
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ropivacaine HCl rectally in 80 mL hydroxypropyl methylcellulose gel
Trial: 11121911
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy based on rabeprazole (20 mg b.d.), clarithromycin (250 mg t.d.s.), and amoxicillin (500 mg t.d.s.)
Trial: 11121911
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy based on rabeprazole (20 mg b.d.), clarithromycin (250 mg t.d.s.), amoxicillin (500 mg t.d.s.) supplemented with a lyophilized and inactivated culture of Lactobacillus acidophilus (t.d.s.)
Trial: 9360784
Drug: G-CSF mobilized
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF mobilized PBSC
Trial: 9360784
Drug: G-CSF vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF vs. GM-CSF
Trial: 3870624
Drug: Ticlopidine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (500 mg)
Trial: 12654171
Drug: Marine oil
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine oil (MO) 600 mg/d providing 150 mg DHA + 30 mg EPA for 6 weeks
Trial: 12654171
Drug: Placebo (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (600 mg sunflower oil/d)
Trial: 11165585
Drug: Elevated umbilical
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated umbilical venous cord blood plasma IL‐6 concentrations (≥10 pg/mL)
Trial: 11165585
Drug: Normal umbilical
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal umbilical venous cord blood plasma IL‐6 concentrations (<10 pg/mL)
Trial: 9553402
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral supplementation with vitamin C, E, and beta-carotene for 21 days
Trial: 7997808
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TPS and CA 125
Trial: 7997808
Drug: TPS and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPS and CA 125 during therapy and follow-up
Trial: 3041630
Drug: aqueous procaine
RxNorm normalized name: Aqueous procaine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aqueous procaine penicillin G (APPG) with 1 g of oral probenecid
Trial: 25381047
Drug: Zoledronate (ZOL)
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronate (ZOL) 4 mg intravenous every 3 months for 24 months
Trial: 15658645
Drug: Tongguan capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongguan capsule (TGC) with Western medicine
Trial: 11320886
Drug: Combined preoperative
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined preoperative radiochemotherapy with hyperthermia (Radiotherapy: 5 x 1.8 Gy up to 45 Gy; Chemotherapy: 5-Fluorouracil 300-350 mg/m2/d and Leucovorin 50 mg; Hyperthermia: SIGMA 60 applicator BSD 2000 once a week).
Trial: 30706488
Drug: Kiwifruit (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kiwifruit (two kiwifruits twice daily for 3 days)
Trial: 30706488
Drug: Control (isocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (isocaloric maltodextrin, twice daily for 3 days)
Trial: 22981147
Drug: LB80380 maleate
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB80380 maleate formulation (183 mg tablet)
Trial: 22981147
Drug: LB80380 free
RxNorm normalized name: Free Cysteine
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LB80380 free base formulation (60 and 90 mg tablets)
Trial: 17888191
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg kg(‐1) propofol followed by 8% sevoflurane
Trial: 14649346
Drug: Meperidine 1
RxNorm normalized name: meperidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 1 mg kg(‐1)
Trial: 10067708
Drug: HIV vaccine
RxNorm normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV vaccine candidates (e.g., live preparations, DNA plasmids)
Trial: 8612313
Drug: Uracil plus
RxNorm normalized name: uracil
DrugBank: Uracil (DB03419)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uracil plus ftorafur (UFT) at 350 mg/m2 plus leucovorin (150 mg daily)
Trial: 24525393
Drug: Paracetamol 1
RxNorm normalized name: Paracetamol 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g twice daily for 12 weeks
Trial: 12116830
Drug: Subcutaneous digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous digital block
Trial: 12116830
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of modified transthecal and subcutaneous digital block
Trial: 17137546
Drug: Amoxicillin (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (7 days)
Trial: 31400933
Drug: PGC preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGC preparation
Trial: 22511495
Drug: High-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose imatinib (800 mg/day for 6 months) followed by standard-dose imatinib (400 mg/day)
Trial: 20547287
Drug: STI-positive adolescents
RxNorm normalized name: STI-1499
DrugBank: STI-1499 (DB16487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STI-positive adolescents who received treatment and counseling
Trial: 17977537
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of ferrous sulfate daily
Trial: 11374853
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy including aggressive lipid control
Trial: 1448776
Drug: Recombinate (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinate (recombinant FVIII preparation)
Trial: 25116967
Drug: Calcitriol ointment
RxNorm normalized name: Calcitriol Ointment
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol ointment (3 mcg/g)
Trial: 25116967
Drug: Betamethasone diproprionate
RxNorm normalized name: betamethasone 0.05 % (betamethasone diproprionate 0.64 MG/ML) Augmented Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone diproprionate ointment (64 mg/g)
Trial: 21756141
Drug: Non-hydrolized carnosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-hydrolized carnosine (Can-C Plus® formulation)
Trial: 30642326
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical exercise programme (2 weekly sessions for 6 months, including at least 30 min of moderate intensity activity)
Trial: 30642326
Drug: Antidepressant drug
RxNorm normalized name: MAO A Inhibitors, antidepressant drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant drug treatment (habitually used in clinical practice)
Trial: 23085365
Drug: GMZ2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMZ2 vaccine in Trichuris trichiura negative subjects
Trial: 23085365
Drug: GMZ2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMZ2 vaccine in Trichuris trichiura positive subjects
Trial: 20518324
Drug: JEV-L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JEV-L
Trial: 2689255
Drug: trimoprostil 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimoprostil 750 micrograms taken 4 times daily
Trial: 6108128
Drug: Flunitrazepam (0.25‐0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (0.25‐0.50 mg)
Trial: 6108128
Drug: Triazolam (0.25‐0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.25‐0.50 mg)
Trial: 6108128
Drug: Brotizolam (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam (0.6 mg)
Trial: 23414763
Drug: Moisturizing Durable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moisturizing Durable Barrier Cream (MDBC)
Trial: 23414763
Drug: 10% Glycerine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Glycerine Cream (Sorbolene)
Trial: 21812264
Drug: Guizhi Fuling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guizhi Fuling Capsule
Trial: 19950299
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral MLN3897 once daily for 12 weeks while continuing to receive MTX once a week
Trial: 19950299
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo once daily for 12 weeks while continuing to receive MTX once a week
Trial: 18722214
Drug: Intranasal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal steroid injection (triamcinolone), 1 cc (20 mg/mL) injected into each inferior turbinate
Trial: 18722214
Drug: Placebo (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isotonic saline), 1 cc injected into each inferior turbinate
Trial: 15702061
Drug: Levobupivacaine Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine Group (L) 30 ml of 0.5% levobupivacaine
Trial: 15702061
Drug: Levobupivacaine Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine Group (L)
Trial: 8150762
Drug: Cefepime 2
RxNorm normalized name: cefepime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 2 g i.v. bd
Trial: 8150762
Drug: Cefotaxime 2
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2 g i.v. tds
Trial: 11795430
Drug: Bowman-Birk Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowman-Birk Inhibitor Concentrate (BBIC)
Trial: 30623534
Drug: Ropivacaine (7.5%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (7.5%, 5 mL)
Trial: 28300812
Drug: placebo naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo naltrexone + guanfacine (NP+G)
Trial: 22267280
Drug: pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pioglitazone (PIO) 30 mg once daily
Trial: 22267280
Drug: metformin (MET)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin (MET) 1000 mg twice daily
Trial: 20337077
Drug: Two-visit endodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-visit endodontic treatment (calcium hydroxide as interappointment medicament)
Trial: 17377528
Drug: Acetaminophen 4
RxNorm normalized name: acetaminophen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 4 then 6 g/day
Trial: 17377528
Drug: Acetaminophen 4
RxNorm normalized name: acetaminophen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 4 then 8 g/day
Trial: 11879108
Drug: Nonoxynol-9 gel
RxNorm normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoxynol-9 gel (100 mg) and condoms
Trial: 10434239
Drug: Cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (200 mg twice daily)
Trial: 8574711
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily plus Cisapride 20 mg twice daily
Trial: 8574711
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily alone
Trial: 2186273
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (100 U/kg thrice weekly by intravenous bolus)
Trial: 25902327
Drug: Prophylactic oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic oxytocin infusion at 44.2 IU/h (ED90) in laboring women
Trial: 25902327
Drug: Prophylactic oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic oxytocin infusion at 16.2 IU/h (ED90) in nonlaboring women
Trial: 25902327
Drug: Requirement for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Requirement for additional uterotonic agents in laboring women
Trial: 25902327
Drug: Requirement for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Requirement for additional uterotonic agents in nonlaboring women
Trial: 17580734
Drug: Betaxolol, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaxolol, 20 mg once daily
Trial: 17580734
Drug: Metoprolol tartrate,
RxNorm normalized name: Metoprolol Tartrate, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol tartrate, 50 mg twice daily
Trial: 15090020
Drug: Topical tazarotene
RxNorm normalized name: tazarotene Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tazarotene 0.1% cream applied BID
Trial: 8431341
Drug: Intra-articular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular morphine 5 mg in saline 25 ml
Trial: 8431341
Drug: Saline 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 25 ml intra-articularly (Control)
Trial: 29166890
Drug: Continuous passive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous passive motion (CPM) in combination with early motion Physical Therapy (PT) supervised by a physical therapist
Trial: 29166890
Drug: Early motion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early motion Physical Therapy (PT) supervised by a physical therapist
Trial: 29166890
Drug: Outpatient supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient supervised Physical Therapy (PT) from postoperative day seven till ten
Trial: 26405670
Drug: Topical and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical and systemic antibiotics
Trial: 23955055
Drug: Both counseling
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both counseling and nicotine patch
Trial: 18280205
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (1000mg)
Trial: 17009270
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone (15 mg/kg of ideal body weight/day)
Trial: 1950033
Drug: Lovastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 80 mg
Trial: 31504554
Drug: GHB (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB (50 mg/kg body weight)
Trial: 28335841
Drug: ASV plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASV plus optimized medical therapy (OMT)
Trial: 23444286
Drug: Doxylamine/pyridoxine delayed-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxylamine/pyridoxine delayed-release combination (Diclectin)
Trial: 21148606
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol (Group C)
Trial: 2405737
Drug: 10 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms/kg atropine followed by 0.1 ml/kg 1% lidocaine with 1/200,000 epinephrine (0.5 micrograms/kg)
Trial: 2405737
Drug: 0.1 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml/kg 1% lidocaine with 1/200,000 epinephrine (0.5 micrograms/kg) without atropine
Trial: 2405737
Drug: 10 micrograms/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms/kg atropine followed by 0.1 ml/kg 1% lidocaine without epinephrine
Trial: 2405737
Drug: 0.1 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml/kg 1% lidocaine without epinephrine without atropine
Trial: 6776586
Drug: Diazepam (moderate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (moderate doses)
Trial: 22105872
Drug: Standard-dose IVLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose IVLE (0.5 g kg(‐1) day(‐1) gradually increased to a maximum of 3.5 g kg(‐1) day(‐1))
Trial: 22105872
Drug: Restricted-dose IVLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted-dose IVLE (1 g kg(‐1) day(‐1))
Trial: 22105872
Drug: Standard-dose IVLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose IVLE
Trial: 22105872
Drug: Restricted-dose IVLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted-dose IVLE
Trial: 16032969
Drug: New divisible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New divisible formulation of lamotrigine (100 mg)
Trial: 16032969
Drug: Plain lamotrigine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain lamotrigine tablet
Trial: 16032969
Drug: Dispersible/chewable lamotrigine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible/chewable lamotrigine tablet
Trial: 7571982
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (ascites and very low sodium excretion)
Trial: 6820076
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition regimen with lipid emulsion
Trial: 6820076
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition regimen without lipid emulsion
Trial: 31151800
Drug: 0.3 mL
RxNorm normalized name: ethanol 0.3 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mL of GC1109
Trial: 31151800
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL of GC1109
Trial: 31151800
Drug: 1.0 mL
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mL of GC1109
Trial: 31151800
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline 0.5 mL)
Trial: 26242443
Drug: Continuous diclofenac
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous diclofenac (150 mg/day)
Trial: 26242443
Drug: Continuous diclofenac
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous diclofenac (150 mg/day) in C reactive protein positive or syndesmophytes patients
Trial: 26242443
Drug: Continuous diclofenac
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous diclofenac (150 mg/day) in patients with syndesmophytes
Trial: 15240611
Drug: hPTH (1-34)
RxNorm normalized name: (LEU27)-CYCLO(GLU22-LYS26)-HPTH-(1-31)-NH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hPTH (1-34) 400 U daily for 12 months
Trial: 9572541
Drug: Loteprednol etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loteprednol etabonate (LE), n=10, instilled one drop into each eye 8 times daily on Days 0 and 1 and four times daily on Days 2 through 42
Trial: 9572541
Drug: Placebo, n=4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, n=4, instilled one drop into each eye 8 times daily on Days 0 and 1 and four times daily on Days 2 through 42